19 results about "Risperidone" patented technology

The invention discloses a pharmaceutical composition for improving biphasic depression and a pharmaceutical preparation and application thereof, and belongs to the technical field of research and development of biphasic depression drugs, the pharmaceutical composition is composed of nicotine and a second-generation antipsychotic drug, and the second-generation antipsychotic drug is quetiapine or risperidone. Experiments prove that the combined use of the nicotine and the second-generation antipsychotic has a synergistic effect in the aspect of improving the manic behavior of biphasic depression and has a better effect of improving the biphasic depression compared with the independent use of the nicotine and the second-generation antipsychotic.

Disclosed is a compound sustained release implant of naltrexone and risperidone, and a preparation method and application thereof, which belong to the technical field of implant preparation. The naltrexone compound sustained-release implant includes naltrexone, risperidone, a degradable material A, a degradable material B, an additive and a lubricant. By controlling a mass ratio of naltrexone to risperidone to be (20-30):1, a weight-average molecular weight of the degradable material A to be 10-15W, and a weight-average molecular weight of the degradable material B in risperidone microspheres to be 2W-4W, the compound sustained release implant of naltrexone and risperidone can not only effectively inhibit amphetamine type drug relapse and reduce side effects of risperidone, but also realize the synchronous release of naltrexone and risperidone.

The invention discloses a composition, a method and a system for predicting the applicability of antipsychotic drugs. The invention develops a composition, a detection kit, a model construction method and a system for predicting the applicability of antipsychotic drugs on the basis of selected SNP site information. Particularly, a gene marker combination related to the curative effects of the antipsychotic drugs olanzapine, risperidone, aripiprazole and quetiapine is found by adopting a large-sample high-throughput whole-genome association analysis technology, and a corresponding mathematical model for predicting the curative effects is constructed; the model can be used for predicting the PANSS subtraction rate after the schizophrenia is treated by medication based on DNA polymorphic sites and clinical basic information of a medication user in a high, medium and low classification manner, and assists in guiding the selection of the types of the medication, so that personalized treatment of the schizophrenia patient is realized.

The present application relates to a lurasidone hydrochloride pharmaceutical composition and a preparation method thereof. The present application discloses a lurasidone hydrochloride pharmaceutical composition, which comprises lurasidone hydrochloride and a stabilizer, wherein the lurasidone hydrochloride is in nanoscale. The prepared lurasidone hydrochloride pharmaceutical composition can improve the solubility and bioavailability of the drug, and reduce the influence of food effect. The preparation method of the present application is simple in operation, low in production cost and easy to realize industrialized scale-up production.

This application relates to a method for detecting related substances in a pharmaceutical composition containing naltrexone and risperidone, comprising the following steps: preparing a test solution from the pharmaceutical composition containing naltrexone and risperidone; and detecting the test solution using high-performance liquid chromatography (HPLC), wherein the HPLC detection conditions include: (1) a chromatographic column consisting of a C18 column and a silica-bonded phenyl column arranged in series; and (2) mobile phases A, B, and C being buffer solutions, acetonitrile, and methanol at different volume percentages, respectively; each buffer solution being an aqueous solution of sodium octanesulfonate with a pH of 2.25–2.35. The detection method can effectively separate and detect multiple related substances in a pharmaceutical composition containing naltrexone and risperidone.

The invention relates to the field of blood concentration detection, in particular to a risperidone blood concentration detection method, and provides a risperidone blood concentration detection method based on a low-temperature extraction scheme, the risperidone blood concentration detection method reduces risperidone decomposition and loss in the impurity removal process, and the risperidone purity is improved. The method has better detection accuracy in high-concentration and low-concentration samples.

The application discloses a purification method of a risperidone intermediate, 6-fluoro-3-(4-piperidyl)-1,2-benzisoxazole hydrochloride shown in formula II, characterized in that the purification method comprises the following steps: adding 6-fluoro-3-(4-piperidyl)-1,2-benzisoxazole hydrochloride into ethanol, adding a certain amount of water, heating to reflux until the solution is clear, cooling to a certain temperature to perform crystal growing, then cooling to-5-10 DEG C, filtering and drying to obtain the product. The purification method of 6-fluoro-3-(4-piperidyl)-1,2-benzisoxazole hydrochloride provided by the application can effectively separate the formula V dimer, the purification yield is more than 85%, the chemical purity of the finished product can reach more than 99.9%, and the method will not produce amplification effect in mass production, and the process is stable.

The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg / ml and injection volume is 1 mL or less.

Disclosed are administration regimens for gastroretentive systems containing risperidone or a salt thereof. The administration regimens include a regimen in which immediate-release risperidone or a salt thereof is administered for a first period, a gastroretentive system containing immediate-release risperidone or a salt thereof and risperidone or a salt thereof is administered for a second period, and a gastroretentive system containing risperidone or a salt thereof is administered for a third period. Also included are regimens in which immediate-release risperidone or a salt thereof and a gastroretentive system containing risperidone or a salt thereof are administered during a co-administration period, followed by a gastroretentive system containing risperidone or a salt thereof.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a domperidone impurity detection method. According to the domperidone impurity detection method, the impurity A, the impurity B, the impurity C, the impurity D + E, the impurity F, the impurity H, the impurity I and the impurity J in domperidone can be detected, the separation degree of each impurity peak is high, and the content of each impurity can be measured at the same time. The detection method disclosed by the invention is good in specificity, high in sensitivity and good in experimental verification results such as linearity, repeatability, solution stability and accuracy inspection. The result provides a new method for impurity detection of domperidone, and provides guarantee for preparation of domperidone tablets and other preparations.

A method of treating an episode of acute exacerbation of schizophrenia by intramuscular administration of a long-acting injectable depot composition containing risperidone is provided. The method provides a substantial reduction in PANSS (both positive and negative scales) and CGI-S scores within about eight days after administration of the composition and for up to at least four weeks. The method is used to treat a subject suffering a first-time episode of or a relapse of severe to moderate symptoms associated with schizophrenia. The method does not require loading doses of risperidone in the depot composition and does not require supplementation with oral risperidone after administration of the depot composition.

A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRD1-like family, of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting an upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using an antipsychotic which directly targets the DRD1 / 5 promoter. The antipsychotics being used are typical and / or atypical antipsychotic medications such as Haloperidol,Risperidone, Clozapine and Cariprazine. The treatment is also useful for the subject with an impaired constitutive expression of DRD1 / 5 gene. The method can be used to treat schizophrenia, autism, depression, mania and bipolar disorders by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening through comparing with a standard sequence database.

The invention discloses application of a depression treatment target TMEM132E in reutilization of depression drugs, and relates to the technical field of crude drugs and molecular biology. According to the invention, TMEM132E is taken as a core target spot, and marketed drugs capable of targeting interaction of TMEM132E and TrkB are screened and verified, namely pimozide, lybramer and risperidone. The three can significantly enhance the formation of a TMEM132E-TrkB compound, restore the activity of a BDNF / TrkB signal pathway, activate a downstream ERK signal, and improve the pathologic state related to depression. According to the invention, TMEM132E is determined as a precise target for reutilization of the depression drug for the first time, the related technical blank is filled, the safety of the selected drug is clinically verified, the research and development period can be greatly shortened, the cost is reduced, a new path is developed for treatment of depression, and meanwhile, the synergistic potential of combined application of the drug and the existing antidepressant drug is prompted.

The application belongs to the technical field of medicine, and particularly relates to application of eldecalcitol combined with risperidone in improving schizophrenia and preventing and treating risperidone side effect osteoporosis. Specifically, the application proves that, by inhibiting hippocampal gamma-aminobutyric acid neuron iron death, the eldecalcitol restores brain neurotransmitter homeostasis, thereby improving schizophrenia in cooperation with risperidone; meanwhile, the eldecalcitol relieves risperidone-induced osteoporosis by regulating neural pathways and a direct pathway of preventing osteoblast iron death. Therefore, the application brings a new breakthrough to the treatment field of schizophrenia, and realizes the clinical effect of 'one arrow with two effects' by developing the combination of the eldecalcitol and the risperidone, so as to provide a new hope and direction for the treatment of schizophrenia patients, and therefore has a good practical application value.

The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg / mL. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally further comprises the step of administering a therapeutically effective dose of dopamine-antagonist to the subject such as risperidone. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally comprises providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, and empty capsids.

The present invention relates to a risperidone transdermal administration system. More specifically, the present invention relates to a transdermal administration system for continuously delivering risperidone or a pharmaceutically acceptable salt thereof at a therapeutically effective amount of blood drug concentration within 24 hours to 14 days, and a preparation method therefor and a use thereof.

The application discloses a nucleic acid aptamer and derivatives, application and kit capable of specifically combining with risperidone, comprising a nucleotide sequence shown in SEQ ID No. 1, or a nucleotide sequence with high homology with the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with risperidone, or a nucleotide sequence derived from the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with risperidone. The application provides a nucleic acid aptamer and derivatives capable of combining with risperidone, which have high specificity, stable chemical properties, are easy to preserve and label, and also correspondingly provides a screening method and application of the nucleic acid aptamer.

The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg / mL. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally further comprises the step of administering a therapeutically effective dose of dopamine-antagonist to the subject such as risperidone. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally comprises providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, and empty capsids.

The invention relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition responsive to risperidone or to paliperidone with risperidone in a subject who receives one or more inhibitors of the enzyme CYP2D6 (cytochrome P450 2D6). The invention also relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition responsive to risperidone or to paliperidone with risperidone and for simultaneously treating a disease, disorder or condition responsive to CYP2D6 enzyme inhibitor in a subject. The invention further relates to prolonged-release injectable compositions containing risperidone and a CYP2D6 enzyme inhibitor, wherein the dose of risperidone does not need to be reduced according to the administered dose of CYP2D6 inhibitor.